Bullish Case: Post-crash washout skews asymmetric: six-of-eight complete remissions at top dose, zero discontinuations, and the known Phase 3 adjuvant pivot keep dabogratinib viable; a fuller fall dataset (inferred Oct congress) could reframe Sept 9's headline miss. Calls out-traded puts 73%, price rebounded +15.5% weekly, SPY's tame 12–25 vol leaves TYRA idiosyncratic, and both PDFs show upside modes—market density ~0.08 at $32.5–35. Backwardation prices pain now; de-risking compresses IV fast.

Bearish Case: Reality check: 6/8 CRs is a tiny marker-lesion slice versus Zusduri's 78% and Balversa's 89% comparators, and the adjuvant Phase 3 must enroll tougher non-marker-lesion patients. Stock is still -10.2% over 90 days; Sept 18 expiry carries 200%+ IVs, deep-put wings price 120–500 vol, and the historical return surface's -75% left tail is real. Enrollment friction, safety wobble, or financing need reopens a fast -35–60% gap.

Potential Outcomes: Calibration: July's 40% mixed-band call matched Sept 9; the 25% beat case failed—misses ran hot as feared.

1. 35% $23–28 digestion, IV decay; falsified by <$22 or >$28.
2. 30% Fall data + Phase 3 start reframe → $30–35; falsified by enrollment delay.
3. 20% Design/dilution skepticism → $18–22.
4. 10% Hold/safety shock → $12–17.
5. 5% Partnership bid → $35+.

Oracle: backwardation favors Oct–Feb 27.5/32.5 call spreads over rich near-dated premium.

September 16, 2026